- Home
- NEOV vs SCPH Comparison
NEOV vs SCPH Comparison
Compare NEOV & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- SCPH
- Stock Information
- Founded
- NEOV 2018
- SCPH 2013
- Country
- NEOV United States
- SCPH United States
- Employees
- NEOV N/A
- SCPH N/A
- Industry
- NEOV Industrial Machinery/Components
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- SCPH Health Care
- Exchange
- NEOV Nasdaq
- SCPH Nasdaq
- Market Cap
- NEOV 153.9M
- SCPH 299.0M
- IPO Year
- NEOV N/A
- SCPH 2017
- Fundamental
- Price
- NEOV $5.20
- SCPH $5.61
- Analyst Decision
- NEOV Strong Buy
- SCPH Buy
- Analyst Count
- NEOV 1
- SCPH 3
- Target Price
- NEOV $7.50
- SCPH $12.00
- AVG Volume (30 Days)
- NEOV 236.7K
- SCPH 2.3M
- Earning Date
- NEOV 11-07-2025
- SCPH 11-12-2025
- Dividend Yield
- NEOV N/A
- SCPH N/A
- EPS Growth
- NEOV N/A
- SCPH N/A
- EPS
- NEOV N/A
- SCPH N/A
- Revenue
- NEOV $4,255,136.00
- SCPH $49,969,000.00
- Revenue This Year
- NEOV $208.50
- SCPH $108.95
- Revenue Next Year
- NEOV $128.75
- SCPH $78.30
- P/E Ratio
- NEOV N/A
- SCPH N/A
- Revenue Growth
- NEOV 52.64
- SCPH 107.79
- 52 Week Low
- NEOV $1.80
- SCPH $1.94
- 52 Week High
- NEOV $6.11
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- NEOV 68.69
- SCPH 63.30
- Support Level
- NEOV $3.40
- SCPH $4.33
- Resistance Level
- NEOV $3.86
- SCPH $5.62
- Average True Range (ATR)
- NEOV 0.35
- SCPH 0.04
- MACD
- NEOV 0.19
- SCPH 0.00
- Stochastic Oscillator
- NEOV 89.60
- SCPH 78.57
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.